Tags

Type your tag names separated by a space and hit enter

Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
J Am Geriatr Soc. 2011 Nov; 59(11):2084-90.JA

Abstract

OBJECTIVES

To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once- Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study.

DESIGN

Randomized, placebo-controlled, double-blind trial.

SETTING

International multicenter.

PARTICIPANTS

Five hundred and eight men and 1,619 women within 90 days of surgical repair of low-trauma hip fracture in the same study (for comparison).

INTERVENTION

Once-yearly intravenous (IV) ZOL 5 mg (n = 248) or placebo (n = 260), loading dose of vitamin D, daily calcium, and vitamin D supplements.

MEASUREMENT

Changes in BMD.

RESULTS

Percentage change from baseline in total hip BMD at Months 12 and 24 was significantly higher with ZOL than with placebo (between-group difference, 2.0%, P = .003, and 3.8%, P = .002, respectively). Percentage change from baseline in femoral neck BMD at Month 24 was significantly higher with ZOL than with placebo (3.8%, P = .003). The BMD benefit was comparable with that observed in women in this study. New clinical fractures occurred in 36 (7.1%) participants (ZOL, n = 16; placebo, n = 20; P = .64). The ZOL safety profile was comparable with that of placebo, with no significant differences in cardiovascular or long-term renal function and a trend toward lower mortality in ZOL-treated men.

CONCLUSION

Once-yearly IV ZOL 5 mg increases bone mass at the hip and femoral neck in men within 90 days of repair of a low-trauma hip fracture. Increases were of a similar magnitude to those observed in women in the same study.

Authors+Show Affiliations

Center for Musculoskeletal Research, Leuven University, Leuven, Belgium. boonen@uz.kuleuven.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

22091563

Citation

Boonen, Steven, et al. "Once-yearly Zoledronic Acid in Older Men Compared With Women With Recent Hip Fracture." Journal of the American Geriatrics Society, vol. 59, no. 11, 2011, pp. 2084-90.
Boonen S, Orwoll E, Magaziner J, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. J Am Geriatr Soc. 2011;59(11):2084-90.
Boonen, S., Orwoll, E., Magaziner, J., Colón-Emeric, C. S., Adachi, J. D., Bucci-Rechtweg, C., Haentjens, P., Kaufman, J. M., Rizzoli, R., Vanderschueren, D., Claessens, F., Sermon, A., Witvrouw, R., Milisen, K., Su, G., & Lyles, K. W. (2011). Once-yearly zoledronic acid in older men compared with women with recent hip fracture. Journal of the American Geriatrics Society, 59(11), 2084-90. https://doi.org/10.1111/j.1532-5415.2011.03666.x
Boonen S, et al. Once-yearly Zoledronic Acid in Older Men Compared With Women With Recent Hip Fracture. J Am Geriatr Soc. 2011;59(11):2084-90. PubMed PMID: 22091563.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Once-yearly zoledronic acid in older men compared with women with recent hip fracture. AU - Boonen,Steven, AU - Orwoll,Eric, AU - Magaziner,Jay, AU - Colón-Emeric,Cathleen S, AU - Adachi,Jonathan D, AU - Bucci-Rechtweg,Christina, AU - Haentjens,Patrick, AU - Kaufman,Jean-Marc, AU - Rizzoli,Rene, AU - Vanderschueren,Dirk, AU - Claessens,Frank, AU - Sermon,An, AU - Witvrouw,Richard, AU - Milisen,Koen, AU - Su,Guoqin, AU - Lyles,Kenneth W, AU - ,, Y1 - 2011/10/21/ PY - 2011/11/19/entrez PY - 2011/11/19/pubmed PY - 2012/1/13/medline SP - 2084 EP - 90 JF - Journal of the American Geriatrics Society JO - J Am Geriatr Soc VL - 59 IS - 11 N2 - OBJECTIVES: To assess the efficacy of once-yearly zoledronic acid (ZOL) 5 mg in increasing bone mineral density (BMD) in men with a recent hip fracture participating in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once- Yearly Recurrent Fracture Trial and to compare the efficacy with that in women from the same study. DESIGN: Randomized, placebo-controlled, double-blind trial. SETTING: International multicenter. PARTICIPANTS: Five hundred and eight men and 1,619 women within 90 days of surgical repair of low-trauma hip fracture in the same study (for comparison). INTERVENTION: Once-yearly intravenous (IV) ZOL 5 mg (n = 248) or placebo (n = 260), loading dose of vitamin D, daily calcium, and vitamin D supplements. MEASUREMENT: Changes in BMD. RESULTS: Percentage change from baseline in total hip BMD at Months 12 and 24 was significantly higher with ZOL than with placebo (between-group difference, 2.0%, P = .003, and 3.8%, P = .002, respectively). Percentage change from baseline in femoral neck BMD at Month 24 was significantly higher with ZOL than with placebo (3.8%, P = .003). The BMD benefit was comparable with that observed in women in this study. New clinical fractures occurred in 36 (7.1%) participants (ZOL, n = 16; placebo, n = 20; P = .64). The ZOL safety profile was comparable with that of placebo, with no significant differences in cardiovascular or long-term renal function and a trend toward lower mortality in ZOL-treated men. CONCLUSION: Once-yearly IV ZOL 5 mg increases bone mass at the hip and femoral neck in men within 90 days of repair of a low-trauma hip fracture. Increases were of a similar magnitude to those observed in women in the same study. SN - 1532-5415 UR - https://www.unboundmedicine.com/medline/citation/22091563/Once_yearly_zoledronic_acid_in_older_men_compared_with_women_with_recent_hip_fracture_ L2 - https://doi.org/10.1111/j.1532-5415.2011.03666.x DB - PRIME DP - Unbound Medicine ER -